Objective: The aim of this study is to investigate whether Hemoglobin A1c (HbA1c) levels in polycystic ovary syndrome (PCOS) can predict the risk of fibrocystic breast disease in women applied to the Gynecology&Obstetrics outpatient clinic. Method: This retrospective study was conducted from January 2018 to February 2020 on 269 women. The subjects were divided into two groups as PCOS group (Group 1) and control group (Group 2), respectively. Results: The mean age of all participants was 33.13 ±

more »

... 1.93 years. Most of the subjects had normal Body mass index (BMI) (35.3%; 25.7 ± 1.44). 50.6 % had the risk of fibrocystic breast disease. The mean age of menarche was 11.36 ± 0.97, and the mean level of HbA1c was 5.57 ± 0.37. FSH (p< 0.001), LH (p< 0.001), HbA1c (p = 0.001), fasting glucose (p = 0.001) and AMH (p = 0.001) were significantly different between the two groups. Prevalence of fibrocystic breast disease and smoking (p=0.03 and 0.02, respectively) were significantly different at HbA1c levels among the control group. There was a statistically significant difference (p=0.04 and 0.04) between the fibrocystic breast disease and HbA1c levels i.e. 5.7≤ HbA1c ≤6 and HbA1c >6 in the control group. Conclusions: It was concluded that HbA1c cannot be used for assessment of the fibrocystic breast disease in the PCOS women but can predict the fibrocystic breast disease in healthy women. There may be a need for additional diagnostic tests for the PCOS women to assess the fibrocystic breast disease for early treatment. ÖZET Amaç: Bu çalışmanın amacı; kadın doğum polikliniğne Polikistik over sendromu (PKOS) ile başvuran kadınlarda, Hemoglobin A1c (HbA1c) düzeylerinin, fibrokistik meme hastalığı riskini öngörüp öngöremeyeceğini araştırmaktır. Yöntem: Bu retrospektif çalışma, Ocak 2018-Şubat 2020 tarihleri arasında polikliniğe başvuran 269 kadın üzerinde gerçekleştirilmiştir. Katılımcılar, sırayla, PCOS grubu (Grup 1) ve kontrol grubu (Grup 2) olarak iki gruba ayrılmıştır. Bulgular: Tüm katılımcıların yaş ortalaması 33,13 ± 1,93 olup, katılımcıların çoğunun vücut kitle indeksi (VKİ) normal düzeydedir (% 35.3; 25.7 ± 1.44). Katılımcıların %50.6'sı için fibrokistik meme hastalığı riski söz konusudur. Katılımcıların ortalama menarş yaşı 11.36 ± 0.97, ortalama HbA1c seviyesi ise 5.57 ± 0.37'dir. FSH (p <0.001), LH (p <0.001), HbA1c (p = 0.001), açlık glikozu (p = 0.001) ve AMH (p = 0.001) düzeylerinin iki grup arasında anlamlı farklılık